Breakthrough T1D and ISPAD Announce 2023 Fellows
Breakthrough T1D and ISAPD announce the recipients of the 2023 fellowships. These fellowships will help bring the best in T1D…
We are Grateful to be a Part of the T1D Community
In 2023, we have made tremendous progress in accelerating cures, improving lives, and advocating for people with T1D and their…
Life with T1D: 19 Things I’ve Learned in 19+ Years
A guest post from Breakthrough T1D's social media manager, Grace Bennett, about life-with-T1D lessons she's learned in 19+ years.
FDA-Approved Immune Therapy Shows Benefit in Newly Diagnosed
In a Breakthrough T1D-funded clinical trial and published in the New England Journal of Medicine, baricitinib preserved beta cell function…
ISPAD Annual Conference Highlights Include Tzield, Kidney Disease Clinical Trial Updates
Leading diabetes researchers gathered for the annual ISPAD conference. More than 45 studies were presented by Breakthrough T1D researchers, including…
Results Are Out: Tzield Benefits Newly Diagnosed Individuals
A new study published in the New England Journal of Medicine shows Tzield can preserve beta cell health in certain…
Insulin resistance and type 1 diabetes
We take a closer look at what insulin resistance is, the risks associated with it for people with type 1…
Top Diabetes Researchers Gather for the ISPAD Annual Conference
Leading researchers from around the world will gather for the ISPAD annual conference, with more than 45 studies presented by…
EASD Meeting Brought Together World-Renowned Minds in Diabetes Research
Leading researchers gathered for the annual meeting of the European Association for the Study of Diabetes (EASD), which took place…
Top Researchers Gather for the EASD Annual Meeting
Leading researchers will gather for the annual meeting of the European Association for the Study of Diabetes, with 65 presentations…
